Neurocrine (NBIX) Biosciences announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company’s investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $158 from $163 at Canaccord
- Strong Market Positioning and Growth Potential for Neurocrine’s Ingrezza Amidst Short-term Challenges
- Neurocrine announces publication of a post-hoc analysis of Ingrezza
- Optimistic Buy Rating for Neurocrine Due to Crenessity’s Potential in CAH Treatment
- Neurocrine price target lowered to $168 from $185 at H.C. Wainwright